Unknown

Dataset Information

0

Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions.


ABSTRACT: Parkinson's disease is a neurodegenerative disorder mainly characterized by the degeneration of dopaminergic neurons in the substantia nigra. Degenerating neurons contain abnormal aggregates called Lewy bodies, that are predominantly composed of the misfolded and/or mutated alpha-synuclein protein. Post-translational modifications, cellular stress, inflammation and gene mutations are thought to trigger its pathological misfolding and aggregation. With alpha-synuclein pathology being strongly associated with dopaminergic neuronal toxicity, strategies aimed to reduce its burden are expected to be beneficial in slowing disease progression. Moreover, multiple sources of evidence suggest a cell-to-cell transmission of pathological alpha-synuclein in a prion-like manner. Therefore, antibodies targeting extra- or intracellular alpha-synuclein could be efficient in limiting the aggregation and transmission. Several active and passive immunization strategies have been explored to target alpha-synuclein. Here, we summarize immunotherapeutic approaches that were tested in pre-clinical or clinical studies in the last two decades in an attempt to treat Parkinson's disease.

SUBMITTER: Castonguay AM 

PROVIDER: S-EPMC7990466 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6174397 | biostudies-literature
| S-EPMC8073727 | biostudies-literature
| S-EPMC3357929 | biostudies-literature
| S-EPMC3978826 | biostudies-other
| S-EPMC10610324 | biostudies-literature
| S-EPMC7884384 | biostudies-literature
| S-EPMC5968093 | biostudies-literature
| S-EPMC5357034 | biostudies-other
| S-EPMC10360137 | biostudies-literature
| S-EPMC9650279 | biostudies-literature